The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology
Open accessAbstract
The limited understanding of the heterogeneity in the treatment response to antidiabetic drugs contributes to metabolic deterioration and cardiovascular complications 1,2, stressing the need for more personalized treatment 1. Although recent attempts have been made to classify diabetes into subgroups, the utility of such stratification in predicting treatment response is unknown 3. We enrolled participants with type 2 diabetes (n = 239, 74 women and 165 men) and features of severe insulin-deficient diabetes (SIDD) or severe insulin-resistant diabetes (SIRD). Participants were randomly assigned to treatment with the glucagon-like peptide 1 receptor agonist semaglutide or the sodium–glucose cotransporter 2 inhibitor dapagliflozin for 6 months (open label). The primary endpoint was the change in glycated haemoglobin (HbA1c). Semaglutide induced a larger reduction in HbA1c levels than dapagliflozin (mean difference, 8.2 mmol mol−1; 95% confidence interval, −10.0 to −6.3 mmol mol−1), with a pronounced effect in those with SIDD. No difference in adverse events was observed between participants with SIDD and those with SIRD. Analysis of secondary endpoints showed greater reductions in fasting and postprandial glucose concentrations in response to semaglutide in participants with SIDD than in those with SIRD and a more pronounced effect on postprandial glucose by dapagliflozin in participants with SIDD than in those with SIRD. However, no significant interaction was found between drug assignment and the SIDD or SIRD subgroup. In contrast, continuous measures of body mass index, blood pressure, insulin secretion and insulin resistance were useful in identifying those likely to have the largest improvements in glycaemic control and cardiovascular risk factors by adding semaglutide or dapagliflozin. Thus, systematic evaluation of continuous pathophysiological variables can guide the prediction of the treatment response to these drugs and provide more information than stratified subgroups (NCT04451837).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Extended Data Fig. 2 Changes over time of estimated glomerular filtration rate and liver parameters. Data show means and SD of estimated glomerular filtration rate (eGFR), alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (ALP), bilirubin and NAFLD liver fat score in response to each study drug in SIDD and SIRD participants, respectively, obtained at baseline (0) and after 6 months of treatment (eGFR was also measured at 3 months). Data represent n = 57 dapagliflozin in SIDD [16 women, 41 men]; n = 47 dapagliflozin in SIRD [14 women, 33 men]; n = 49 semaglutide in SIDD [14 women, 35 men]; n = 44 semaglutide in SIRD [16 women, 28 men]; numbers include participants who underwent blood sampling both at baseline and at 6 months. Source data](https://figures.cochat.ai/paper-figures/c44317b307f14726a37fca7bb2238191/randomized-open-label-trial-of-semaglutide-and-dapagliflozin-in-patients-with-figure-4.jpg)
![Extended Data Fig. 3 Relative importance of continuous baseline variables in predicting the change in HbA1c. Panels A and B show the relative importance of baseline variables (features) in predicting the change in HbA1c after treatment with dapagliflozin (n = 113 [31 women, 82 men]; panel A) or semaglutide (n = 107 [36 women, 71 men]; panel B). The full analysis set was included in these analyses, independent of SIDD or SIRD cluster, to investigate the continuous baseline variables across all individuals. The measures of relative feature importance sum up to 1 and were generated by XGBoost. The XGBoost algorithm per se is not intended to be used in routine clinical work but was employed here to identify continuous baseline variables that predict the change in HbA1c and which can easily be evaluated by clinicians to provide a better overall assessment of the likely treatment response (such that for example a patient with high BMI or low insulin secretion will likely have a more pronounced response to a particular drug) in conjunction with other clinical data and the general patient context. Blue bars indicate greater reduction in HbA1c with higher values of the baseline trait; red indicates greater reduction in HbA1c with lower values of the baseline trait (lower BMI is for example associated with greater improvement of HbA1c in response to dapagliflozin). Blue indication for the sex term implies greater reduction in women and red indicates greater reduction in men. BMI is body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; eGFR estimated glomerular filtration rate; DI disposition index; ISI insulin sensitivity index; glucose at 120 min refers to glucose measured at 120 minutes. Time in range (the fraction of time with glucose between 3.9 and 10.0 mmol/l) and CV glucose (coefficient of variance of glucose) were obtained from continuous glucose monitoring during two weeks prior to treatment allocation. Source data](https://figures.cochat.ai/paper-figures/d6f028ecb30644858f8960a8fd2bef50/randomized-open-label-trial-of-semaglutide-and-dapagliflozin-in-patients-with-figure-5.jpg)
![Extended Data Fig. 4 SHAP summary plots for the impact of baseline variables in predicting the change in HbA1c in response to dapagliflozin (upper panel) or semaglutide (lower panel). Each point in the figure corresponds to a participant, and the SHAP value reflects the impact of the baseline variable in predicting the change in HbA1c for that individual. For example, in the row corresponding to HbA1c in the upper panel, all individuals receiving dapagliflozin are plotted in accordance with how much baseline HbA1c predicts the change in HbA1c, and similar for BMI, SBP etc. Thus, for some participants, HbA1c may be a strong predictor and BMI less important, while for other individuals BMI may be the most important predictor. The variables are therefore arranged based on the mean of the absolute SHAP values for each variable. Upper panel shows data for dapagliflozin (n = 113 [31 women, 82 men]) and lower panel shows semaglutide (n = 107 [36 women, 71 men]). SBP denotes systolic blood pressure, DBP diastolic blood pressure, DI disposition index, ISI insulin sensitivity index, and CV glucose denotes coefficient of variation of glucose during continuous monitoring. Source data](https://figures.cochat.ai/paper-figures/f4241f7635874347a854cb38bb766e1c/randomized-open-label-trial-of-semaglutide-and-dapagliflozin-in-patients-with-figure-6.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The study results suggest that semaglutide may be a more suitable choice for patients with severe insulin deficiency, while dapagliflozin might be effective for a broader range of patients with metabolic abnormalities.476”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [476]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It was found that semaglutide performed better than dapagliflozin in reducing HbA1c levels.476”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [476]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 2×
“Extensive evidence has shown that improved control of HbA1c, blood pressure and BMI reduces macrovascular and microvascular events 1,31 .”
Ahlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335
Self-citationDavies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104 · cited 9×
“This is relevant because current guidelines emphasize the potential value of intensifying treatment even in patients with lower glycaemic levels 1,17 .”
InfluentialCorrect Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program
Levy, J. C., Matthews, D. R., & Hermans, M. P. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2191 · Cited by 2,013
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors
Kotronen, A., Peltonen, M., Hakkarainen, A., Sevastianova, K., Bergholm, R., Johansson, L. M., Lundbom, N., Rissanen, A., Ridderstråle, M., Groop, L., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.005 · Cited by 804
Zaharia, O. P., Strassburger, K., Strom, A., Bönhof, G. J., Karusheva, Y., Antoniou, S., Bódis, K., Markgraf, D. F., Burkart, V., Müssig, K., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30187-1 · Cited by 600 · cited 2×
“Similar clusters have been reproduced in several multiethnic cohorts 4–10 .”
Udler, M. S., Kim, J., von Grotthuss, M., Bonàs-Guarch, S., Cole, J. B., Chiou, J., ISGC, C. D. A. O. B. O. M. A. T., Boehnke, M., Laakso, M., Atzmon, G., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002654 · Cited by 542
Management of Hyperglycemia in Type 2 Diabetes
SKOLNIK, N., & OLSON, C. (2012) · Family Practice News · doi:10.1016/s0300-7073(12)70593-5 · Cited by 519
Chilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12572 · Cited by 507
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Diabetes mellitus—Progress and opportunities in the evolving epidemic
Abel, E. D., Gloyn, A. L., Evans-Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Susztak, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 292
Nourazarain, A., & Vaziri, Y. (2025) · Genes & Nutrition · doi:10.1186/s12263-025-00790-9 · Cited by 90
Wu, H., Lv, B., Zhi, L., Shao, Y., Liu, X., Mitteregger, M., Chakaroun, R., Tremaroli, V., Hazen, S. L., Wang, R., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03642-6 · Cited by 77
Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis
Natividade, G. R., Spiazzi, B. F., Baumgarten, M. W., Bassotto, C., Pereira, A. A., Fraga, B. L., Scalco, B. G., Mattes, N. R., Lavinsky, D., Kramer, C. K., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.2489 · Cited by 41
Metadata
- Authors
- Dwibedi, C., Ekström, O., Brandt, J., Adiels, M., Franzén, S., Abrahamsson, B., & Rosengren, A. H.
- Affiliations
- University of Gothenburg (SE)
- Lund University (SE)
- Skåne University Hospital (SE)
- AstraZeneca (Sweden) (SE)
- Corresponding author
- Rosengren, Anders H.
- ORCID
- Venue
- Nature Metabolism
- Published
- 2024-01-04
- Volume
- 6
- Issue
- 1
- Pages
- 50-60
- ISSN
- 2522-5812 (ISSN-L)
- PMC
- PMC10822775
- OpenAlex
- W4390581855
- Cited by
- 40
- References
- 36
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 10
- FWCI
- 13.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- European Commission (HORIZON2020)
- Lunds Universitet (2018–05973)
- Knut och Alice Wallenbergs Stiftelse (2018-05973)
- Vetenskapsrådet (05973, grant agreement no. 2018-05973, 2022-01301, 2018-, 201805973, No. 2018-05973)
- Göteborgs Universitet
- Uppsala Multidisciplinary Center for Advanced Computational Science
- H2020 European Research Council (866510)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, semaglutide, dapagliflozin, GLP-1 receptor agonists, SGLT2 inhibitors, severe insulin-deficient diabetes, severe insulin-resistant diabetes, HbA1c, glycemic control, postprandial blood glucose, insulin secretion, insulin resistance, body mass index, blood pressure, cardiovascular risk factors, treatment response prediction, personalized treatment
- MeSH terms
- Semaglutide, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Glucose, Glucosides, Glycated Hemoglobin, Humans, Insulin, Insulin Resistance, Male, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. https://app.cochat.ai/papers/10.1038/s42255-023-00943-3
- The paper
- Dwibedi, C., Ekström, O., Brandt, J., Adiels, M., Franzén, S., Abrahamsson, B., & Rosengren, A. H. (2024). Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology. Nature Metabolism. https://doi.org/10.1038/s42255-023-00943-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.